BI-847325

立即咨询

BI-847325

本产品不向个人销售，仅用作科学研究，不用于任何人体实验及非科研性质的动物实验。

CAS NO:	1207293-36-4
规格:	≥98%

包装与价格：

包装	价格(元)
5mg	电议
25mg	电议
50mg	电议
100mg	电议
250mg	电议
500mg	电议

产品介绍

BI-847325 (BI847325) is a novel, potent, orally bioavailable, and selective dual inhibitor of MEK (mitogen-activated protein kinase kinase) and Aurora kinase with potential antitumor activity. It inhibits Aurora B, human Aurora A, Aurora C, MEK1 and MEK2 with IC50 of 3 nM, 25 nM, 15 nM, 25 nM, and 4 nM, respectively. BI 847325 shows potent in vitro antiproliferative activity and high in vivo antitumor efficacy.

理化性质和储存条件

Molecular Weight (MW)	464.56
Formula	C29H28N4O2
CAS No.	1207293-36-4
Storage	-20℃ for 3 years in powder form
Storage	-80℃ for 2 years in solvent
Solubility (In vitro)	DMSO: 19 mg/mL (40.9 mM)
	Water: <1 mg/mL
	Ethanol: <1 mg/mL
Solubility (In vivo)	2-hydroxyethyl cellulose, polysorbate 80 with pH adjusted to 2.8 with 1 M HCl: 30 mg/mL
Synonyms	BI 847325; BI847325; BI-847325; (Z)-3-(3-((4-((dimethylamino)methyl)phenylamino)(phenyl)methylene)-2-oxoindolin-6-yl)-N-ethylpropiolamide

实验参考方法

In Vitro	In vitro activity: BI-847325 shows growth-inhibitory effects on BRAF-mutant and vemurafenib-resistant melanoma cells with IC50 ranging from 0.3 nM to 2 μM, and prevents colony formation in six BRAF-mutant melanoma cell lines. BI-847325 also induces apoptosis by reducing Mcl-1 expression Kinase Assay: BI-847325 is an ATP competitive dual inhibitor of MEK and aurora kinases (AK) with IC50 values of 15 and 4 nM for human AK-C and MEK2, respectively. Cell Assay: Cells (M229, M229R, A375, A375R, WM793, WM793R, 1205Lu, 1205LuR, M249, M249R, WM164, WM164R, WM39 and RPMI17951 cells) are plated at a density of 2.5 × 103 cells per 100 μL and left to grow overnight before being treated with increasing concentrations of BI-847325 for 72 hours. The metabolic activity is determined using Alamar blue reagent as per the manufacturer's protocol.
In Vivo	In mice bearing 1205Lu and 1205LuR xenografts, BI-847325 (75 mg/kg, p.o.) causes significant tumor suppression without significant alteration in the body weights
Animal model	Mice bearing 1205Lu and 1205LuR xenografts
Formulation & Dosage	Dissolved in 2-hydroxyethyl cellulose, polysorbate 80 with pH adjusted to 2.8 with 1 M HCl; 70 mg/kg; Oral gavage
References	Mol Cancer Ther. 2015 Jun;14(6):1354-64.

生物活性

The dual MEK and Aurora kinase inhibitor BI-847325 blocks the growth and survival of BRAF-mutant melanoma cell lines through induction of apoptosis. Mol Cancer Ther. 2015 Jun;14(6):1354-64.

BI-847325 induces apoptosis altering the expression of pro and anti-apoptotic proteins. Mol Cancer Ther. 2015 Jun;14(6):1354-64.

Decreased expression of Mcl-1 is required for BI-847325-mediated apoptosis. Mol Cancer Ther. 2015 Jun;14(6):1354-64.

BI-847325-mediated apoptosis is induced following downregulation of Mcl-1. Mol Cancer Ther. 2015 Jun;14(6):1354-64.

BI-847325 leads to decreased MEK expression in BRAF-mutant naive and vemurafenib-resistant cells. Mol Cancer Ther. 2015 Jun;14(6):1354-64.

BI-847325 inhibits growth of BRAF-mutant melanoma xenografts. Mol Cancer Ther. 2015 Jun;14(6):1354-64.